Pricing Log in Create free account
Friday 6 November 2026 Export KRYS’s income statement to Excel — free account

Krystal Biotech, Inc.

KRYS Healthcare Biotechnology

Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.

Revenue
+30.2%
EPS
−22.3%
Free cash flow
+137.8%

Quarter to September 2026, against a year earlier

301.33 1.08 +0.36%
Market cap
$8.9B
P/E
39.2×
Fwd P/E
45.7×
Dividend yield
—
F-score
7/9
Altman Z
39.03
Beneish M
−2.27
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Krystal Biotech, Inc. (KRYS) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Nov 2, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2026 P1I2: 17 added · 4 removed · 46 modified
P2I1A: no comparison — the earlier filing's Item cannot be compared
8-K Oct 15, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Aug 3, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 24 added · 4 removed · 33 modified
P2I1A: no comparison — incorporated by reference
8-K Jul 21, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 15, 2026 5.07 Submission of matters to a vote of security holders
8-K May 4, 2026 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K Feb 17, 2026 2.02 Results of operations and financial condition
10-K Dec 31, 2025 1: 45 added · 20 removed · 86 modified
1A: 7 added · 14 removed · 156 modified
7: 20 added · 62 removed · 59 modified
8-K Jan 11, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jan 8, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Dec 23, 2025 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits Officer departure
8-K Nov 3, 2025 2.02 Results of operations and financial condition
10-Q Sep 30, 2025
8-K Oct 22, 2025 8.01 Other events
8-K Aug 4, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K May 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
10-K Dec 31, 2024
10-Q Sep 30, 2024
8-K Nov 4, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 5, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 26, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 6, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.